Celyad Updates on Leukemia Program at ASH

• Future development of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) program to be underpinned by proprietary OptimAb manufacturing process
• Enrollment of DEPLETHINK trial evaluating CYAD-01 following preconditioning chemotherapy continues, while THINK trial progresses to expansion segment with plans to evaluate monotherapy CYAD-01 produced with OptimAb manufacturing process
• CYCLE-1 trial evaluating next-generation, NKG2D-based CAR-T therapy CYAD-02 following preconditioning chemotherapy on track to begin enrollment in early 2020
• Preliminary results from the r/r AML and MDS program using the OptimAb manufacturing process are expected by the end of first half 2020

https://www.marketscreener.com/news/Celyad-Presents-Update-on-r-r-AML-and-MDS-Program-at-61st-ASH-Annual-Meeting–29703917/